Larazotide formulations
The present invention provides, in part, compositions comprising a peptide that is larazotide or larazotide derivative, or salt thereof, contained within a matrix that provides for controlled release and sustained release formulations. The present invention contemplates that these compositions, formulations and methods can be useful for treating diseases and disorders of the small bowel.
1. An oral composition comprising an effective amount of a peptide that is larazotide or a larazotide derivative, or salt thereof, contained within a biodegradable or erodible polymer matrix comprising microcrystalline cellulose that provides for sustained release of the peptide in simulated intestinal fluid having a pH of 7.0 for at least about 120 minutes;
wherein the composition further comprises an enteric coating that is resistant to dissolution in simulated gastric fluid or simulated intestinal fluid having a pH of 5.5 or less, wherein the composition provides for less than about 25% release of the peptide after two hours in said simulated gastric fluid or simulated intestinal fluid.
2. The composition of claim 1 , wherein the composition releases the peptide or salt thereof in the jejunum and ileum of a human patient.
3. The composition of claim 2 , wherein the composition does not release the peptide or salt thereof in the duodenum.
4. The composition of claim 2 , wherein the composition does not release the peptide or salt thereof in the colon.
5. The composition of claim 1 , wherein the composition comprises a population of beads containing the matrix and an enteric coating.
6. The composition of claim 5 , wherein the enteric coating comprises a co-polymer of methyl acrylate, methyl methacrylate, and methacrylic acid, and the ratio of free carbonyl groups to ester groups in the co-polymer is about 1:10.
7. The composition of claim 6 , wherein the enteric coating is from about 15% to about 40% by weight of the composition.
8. The composition of claim 1 , wherein the matrix comprises a synthetic polymer comprising one or more binders, fillers, or plasticizers.
9. The composition of claim 8 , wherein the binder, filler, or plasticizer comprises one or more of a cellulose or cellulose derivative, fatty acid salt, and synthetic polymer.
10. The composition of claim 1 , wherein the enteric coating comprises a plasticizer which is triethyl citrate.
11. The composition of claim 5 , wherein the beads comprise a top coat or seal coat.
12. The composition of claim 1 , wherein the composition is a capsule for oral delivery comprising a population of beads, the population of beads comprising from 0.25 to 2 mg of larazotide or larazotide derivative or salt thereof contained within an erodible polymer matrix comprising microcrystalline cellulose, the beads further comprising an enteric coating comprising a co-polymer of methyl acrylate, methyl methacrylate, and methacrylic acid.
13. The composition of claim 12 , wherein the ratio of free carbonyl groups to ester groups in the co-polymer is about 1:10.
14. The composition of claim 12 , wherein the enteric coating is from about 20% to about 30% of the total weight of the composition.
15. The composition of claim 9 , wherein the one or more binders, fillers, or plasticizers comprises: a co-polymer of vinyl pyrrolidone and vinyl acetate, or one or more of ethyl cellulose, hydroxypropylmethyl cellulose (HPMC), and carboxymethyl cellulose; and a C8 to C18 fatty acid salt.
16. The composition of claim 15 , wherein the C8 to C18 fatty acid salt is a salt of stearic acid.
17. The composition of claim 15 , wherein the composition provides for sustained release of the peptide in simulated intestinal fluid having a pH of about 7.0 for at least about 180 minutes.